MDD

News

Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD

Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.

News

J&J seeks to rewrite the script on depression treatment

A survey has found that most patients with depression have little hope of being free of their symptoms, and Johnson & Johnson aims to change that.

R&D

an old woman and her middle-aged daughter image for a feature on ageing and neurological conditions

Ageing Europe - It’s time we prioritised neurological condit...

Europeans are living longer than ever before – tangible proof of the phenomenal advancements in science and healthcare.1,2 However, it comes with a paradoxical rise in nervous sy

Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD

J&J seeks to rewrite the script on depression treatment

Ageing Europe - It’s time we prioritised neurological condit...

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks